R&D Trends

Mass Innovation Labs may spur partnerships

Monday, January 11, 2016

Mass Innovation Labs, an accelerated commercialization space, has signed 10 member companies since opening its doors in May 2015, including CRISPR Therapeutics, Imagen Biopharma, Gritstone Oncology, WaveGuide, Radius Health, TCR2 and Editas. Mass Innovation Labs’ member companies account for more than $1 billion in startup R&D capital in one location, and have achieved many important milestones after receiving operational support through the Jumpstart program.

[Read More]

C4 Therapeutics collaborates in the new field of TPD therapeutics

Monday, January 11, 2016

C4 Therapeutics will enter into a strategic collaboration with Roche to develop novel treatments in the field of targeted protein degradation (TPD) using C4’s Degronimid technology. C4’s Degronimids represent a new class of small molecules, TPD therapeutics, which target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the ubiquitin/proteasome system (UPS).

[Read More]

Evotec, UCB ink management agreement

Thursday, January 7, 2016

Evotec has announced an EVT Execute collaboration aimed at providing a complete solution to UCB‘s global sample management requirements. Evotec will manage UCB’s compound collection out of its state-of-the-art sample management facility in Toulouse, France. The agreement covers an initial period of five years.

[Read More]

Quartet Medicine, Merck partner

Thursday, January 7, 2016

Quartet Medicine, a biotechnology company focused on the development of novel treatments for chronic pain and inflammation, has entered into a strategic agreement with Merck, known as MSD outside the U.S. and Canada, in connection with Quartet’s pipeline of novel small molecule drugs modulating the tetrahydrobiopterin (BH4) pathway.

[Read More]